Abeomics

Executive Summary

Abeomics is a San Diego-based biotechnology company founded in 2005 (with an additional founding date of 2013 noted) that specializes in providing research tools and contract research services to the life sciences community. The company's core offerings include recombinant biosimilar antibodies, engineered cell lines, assay kits, recombinant proteins, and custom drug discovery services. Operating primarily in the antibodies and diagnostics sectors, Abeomics serves biotech, pharmaceutical companies, and academic scientists. Despite being a private company with no disclosed funding or valuation, Abeomics has established a niche in the highly competitive reagents and services market by focusing on high-quality, affordable biosimilar antibodies and custom solutions. Abeomics faces intense competition from established players like Bio-Rad, Abcam, and Thermo Fisher, but differentiates itself through its biosimilar approach and contract services. The company's growth potential hinges on expanding its product catalog, forging strategic partnerships, and capitalizing on the increasing demand for research tools and custom services in drug discovery. However, limited public information and lack of disclosed financials constrain visibility into its performance and prospects. Overall, Abeomics occupies a specialized position in the life sciences tools market, with opportunities for steady growth if it can continue to innovate and secure repeat business from its academic and industry clients.

Upcoming Catalysts (preview)

• Q3 2026Launch of Expanded Recombinant Antibody Catalog70% success
• Q4 2026Strategic Partnership with a Mid-Tier Pharma for Custom Drug Discovery Services45% success